文献速递乳腺乳腺X线

开发并验证联合对比增强能谱乳腺X线摄影深度学习与临床病理特征的列线图预测ER阳性/HER2阴性乳腺癌新辅助化疗反应

Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer.
PubMed 文献 · Acad Radiol · 2024-04-18

本研究回顾性纳入265例ER阳性/HER2阴性乳腺癌患者,按4:1随机分为训练集和测试集,基于低能和减影CESM图像构建深度学习模型,结合临床病理特征建立列线图预测新辅助化疗反应(MP-L 1-2级 vs MP-H 3-5级)。列线图AUC达0.95、准确率0.94、特异度0.98、PPV 0.89,优于深度学习模型和临床模型,DCA显示净获益更高。

要点

  • 列线图预测ER阳性/HER2阴性乳腺癌新辅助化疗反应的AUC为0.95,准确率0.94,特异度0.98。
  • 列线图整合CESM深度学习特征与临床病理特征(年龄、PR、ER、Ki67、中性粒细胞与淋巴细胞比值)。
  • 决策曲线分析显示列线图净获益高于深度学习模型和临床模型。

核心结论

  • 整合CESM深度学习与临床病理特征的列线图对预测ER阳性/HER2阴性乳腺癌患者新辅助化疗反应有价值,且优于深度学习模型和临床模型。

研究设计与样本

  • 回顾性研究,纳入265例乳腺癌患者,按4:1随机分为训练集和测试集;深度学习模型基于预训练ResNet34模型(初始针对乳腺癌识别微调),使用低能和减影CESM图像训练;临床模型使用年龄、PR状态、ER状态、Ki67表达水平和中性粒细胞与淋巴细胞比值;通过单变量分析进行特征选择,采用逐步选择法建立和选择逻辑回归模型。

诊断标准与关键数值

  • 预测目标为新辅助化疗反应,分为低Miller Payne(MP-L)1-2级和高MP(MP-H)3-5级;列线图AUC为0.95(P < 0.05),准确率0.94,特异度0.98,PPV 0.89,精确率0.89,均高于深度学习模型和临床模型;评估指标还包括精确率-召回率曲线、ROC曲线、召回率、阴性预测值、平衡准确率、F1分数和决策曲线分析。

临床应用与阅片要点

  • 列线图可用于辅助ER阳性/HER2阴性乳腺癌患者新辅助化疗治疗决策,决策曲线分析显示其净获益高于深度学习模型和临床模型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To develop and validate a nomogram that combines contrast-enhanced spectral mammography (CESM) deep learning with clinical-pathological features to predict neoadjuvant chemotherapy (NAC) response (either low Miller Payne (MP-L) grades 1-2 or high MP (MP-H) grades 3-5) in patients with ER-positive/HER2-negative breast cancer.

MATERIALS AND METHODS: In this retrospective study, 265 breast cancer patients were randomly allocated into training and test sets (used for models training and testing, respectively) at a 4:1 ratio. Deep learning models, based on the pre-trained ResNet34 model and initially fine-tuned for identifying breast cancer, were trained using low-energy and subtracted CESM images. The predicted results served as deep learning features for the deep learning-based model. Clinical-pathological features, including age, progesterone receptor (PR) status, estrogen receptor (ER) status, Ki67 expression levels, and neutrophil-to-lymphocyte ratio, were used for the clinical model. All these features contributed to the nomogram. Feature selection was performed through univariate analysis. Logistic regression models were developed and chosen using a stepwise selection method. The deep learning-based and clinical models, along with the nomogram, were evaluated using precision-recall curves, receiver operating characteristic (ROC) curves, specificity, recall, accuracy, negative predictive value, positive predictive value (PPV), balanced accuracy, F1-score, and decision curve analysis (DCA).

RESULTS: The nomogram demonstrated considerable predictive ability, with higher area under the ROC curve (0.95, P < 0.05), accuracy (0.94), specificity (0.98), PPV (0.89), and precision (0.89) compared to the deep learning-based and clinical models. In DCA, the nomogram showed substantial clinical value in assisting breast cancer treatment decisions, exhibiting a higher net benefit than the other models.

CONCLUSION: The nomogram, integrating CESM deep learning with clinical-pathological features, proved valuable for predicting NAC response in patients with ER-positive/HER2-negative breast cancer. Nomogram outperformed deep learning-based and clinical models.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Xing D, Lv Y, Sun B, et al. Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer. Acad Radiol. 2024. PMID: 38641451. doi:10.1016/j.acra.2024.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。